ALPF Medical Research

Contributors

Guruprasad Padur Aithal Queen's Medical Centre University Hospital, Nottingham, U.K.

Ana Alfirevic Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, U.K.

Maria J. Arranz Section of Clinical Neuropharmacology, Institute of Psychiatry—King's College, London, U.K.

Ian N. Bruce arc Epidemiology Unit, University of Manchester, Manchester, U.K.

John R. Cockcroft Wales Heart Research Institute, Cardiff University, Cardiff, U.K.

Simon Constable Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, U.K.

David N. Cooper Institute of Medical Genetics, Cardiff University, Cardiff, U.K.

Romano Danesi Division of Pharmacology and Chemotherapy, Department of Oncology, University of Pisa, Pisa, Italy

Filippo De Braud Clinical Pharmacology and New Drug Development Unit, European Institute of Oncology, Milano, Italy

Laurent A. Decosterd Division of Clinical Pharmacology, University of Lausanne, Lausanne, Switzerland

Mario Del Tacca Division of Pharmacology and Chemotherapy, Department of Oncology, University of Pisa, Pisa, Italy

Antonello Di Paolo Division of Pharmacology and Chemotherapy, Department of Oncology, University of Pisa, Pisa, Italy

Robert Dingwall Institute for the Study of Genetics, Biorisks and Society, University of Nottingham, Nottingham, U.K.

Charles Eby Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, U.S.A.

Brian Gage Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, U.S.A.

Hakon Hakonarson Division of Inflammation and Pharmacogenomics, deCODE Genetics, Inc., Reykjavik, Iceland

Eva Halapi Division of Inflammation and Pharmacogenomics, deCODE Genetics, Inc., Reykjavik, Iceland

Ian P. Hall Division of Therapeutics and Molecular Medicine, University Hospital of Nottingham, Nottingham, U.K.

Samantha L. Hider arc Epidemiology Unit, University of Manchester, Manchester, U.K.

Reinhold Kerb Experimental Medicine, Astra Zeneca, Molndal, Sweden

Robert W. Kerwin Section of Clinical Neuropharmacology, Institute of Psychiatry—King's College, London, U.K.

Belle L. Lee University of California, San Francisco, California, U.S.A., and Division of Infectious Diseases, Department of Clinical Research, University Hospital, Berne, Switzerland

Stephen B. Liggett Departments of Medicine and Physiology, University of Maryland School of Medicine, Baltimore, Maryland, U.S.A.

Dalu Mancama Section of Clinical Neuropharmacology, Institute of Psychiatry—King's College, London, U.K.

Paul Martin Institute for the Study of Genetics, Biorisks and Society, University of Nottingham, Nottingham, U.K.

Howard L. McLeod Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, U.S.A.

Catharine Morgan arc Epidemiology Unit, University of Manchester, Manchester, U.K.

B. Kevin Park Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, U.K.

Munir Pirmohamed Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, U.K.

Andrew Smart Institute for the Study of Genetics, Biorisks and Society, University of Nottingham, Nottingham, U.K.

Alaisdair C. Stamps UCB-Celltech, Slough, U.K.

Amalio Telenti Institute of Microbiology, University Hospital, University of Lausanne, Lausanne, Switzerland

Jonathan A. Terrett Medarex, Inc., Milpitas, California, U.S.A.

Wendy Thomson arc Epidemiology Unit, University of Manchester, Manchester, U.K.

Monika Werner GSK Glaxo Smith Kline Beecham, Munich, Germany

Matthias Wjst Gruppe Molekulare Epidemiologie, GSF—Forschungszentrum für Umwelt und Gesundheit, Neuherberg/Munich, Germany

Yasmin Clinical Pharmacology Unit, University of Cambridge, Cambridge, U.K.